Biodexa Pharmaceuticals stock more than doubled on Tuesday: explore why

May 21, 2024 08:37 AM PDT | By Invezz

Biodexa Pharmaceuticals stock more than doubled on Tuesday: explore why — Image source: Invezz

Details of the Phase 2 data reported today

The recently licensed drug for FAP (familial adenomatous polyposis) showed non-progression rate of 83% and lowered total polyp burden by about 24% versus the baseline upon six months of treatment.

$BDRX reported two grade 3 adverse events while the remaining 97% of the participants remained on eRapa after six months.

All in all, the Phase 2 data established eRapa as “safe and well-tolerated” on Tuesday.

The news arrives about a month after the pharmaceutical firm reported £0.38 million in consolidate total gross revenue for the full year. Biodexa Pharmaceuticals stock is up roughly 200% versus its year-to-date low at writing.

$BDRX ended 2023 with a loss

Biodexa Pharmaceuticals is scheduled to present the Phase 2 data of eRapa for familial adenomatous polyposis at the annual Digestive Disease event.

Note that the said study was “partially supported by $20 million in grant from the Cancer Prevent and Research Institute” as per the press release on Tuesday.

The Phase 2 trial saw participation from 30 adult patients in total.

$BDRX ended last year with a net loss of £7.08 million – down from a £7.66 million loss in 2022. Biodexa Pharmaceuticals stock does not pay a dividend yield at writing.

The post Biodexa Pharmaceuticals stock more than doubled on Tuesday: explore why appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.